Societal cost-of-illness analysis of self-injection of biologics for patients with rheumatoid arthritis in Japan using claims, surveys, and national statistics
Kazuhiko Takahata, Eiichi Tanaka, Ryoko Sakai, Manabu Akazawa · 2025
Read Societal cost-of-illness analysis of self-injection of biologics for patients with rheumatoid arthritis in Japan using claims, surveys, and national statistics by Kazuhiko Takahata, Eiichi Tanaka, Ryoko Sakai, Manabu Akazawa (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751204.txt.
Description
Kazuhiko Takahata and three co-authors tallied in 2025 what self-injection of biologic drugs costs Japanese society for rheumatoid arthritis patients. They combined insurance claims, a patient survey and national statistics into one annual per-patient figure. The self-injection group spent more on the drugs themselves, near 7,300 dollars, and made fewer clinic trips. Travel costs and lost time both ran lower for them.
Weighing against that, their productivity loss from activity limits ran slightly higher. The near balance of the two totals hides the shifted pattern rather than a tie in every part. Over a ten-year projection the gaps persisted. The authors say self-injection trades drug spending for convenience and fewer visits. They urge policy to look at work capacity and access, not the pharmacy bill alone.
Catalog record
| CREATOR | Kazuhiko Takahata, Eiichi Tanaka, Ryoko Sakai, Manabu Akazawa |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |